Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients with Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial

Keyphrases

• Randomized Clinical Trial 100%
• Thrombomodulin 100%
• Sepsis-induced Coagulopathy 100%
• All-cause Mortality 57%
• Placebo 42%
• Placebo Groups 28%
• Platelet Count 28%
• Intensive Care Unit 28%
• Etiology 14%
• Respiratory Failure 14%
• Randomized Double-blind 14%
• Placebo-controlled 14%
• Adult Patients 14%
• Trial Registration 14%
• Major Bleeding 14%
• Phase II Study 14%
• International Normalized Ratio 14%
• Intracranial Hemorrhage 14%
• Consecutive Days 14%
• Once-daily 14%
• Packed Red Blood Cells 14%
• Intravenous Bolus 14%
• Life-threatening Bleeding 14%
• Bleeding Events 14%
• Absolute Risk Difference 14%
• Bleeding Adverse Events 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Sepsis 100%
• Randomized Clinical Trial 100%
• Blood Clotting Disorder 100%
• Thrombomodulin 100%
• All Cause Mortality 66%
• Recombinant Thrombomodulin 50%
• Respiratory Failure 16%
• Adverse Event 16%
• Mortality Rate 16%
• Bleeding 16%
• Brain Hemorrhage 16%